Aurora Cannabis (TSE:ACB) Trading Down 4.5% - Should You Sell?

Key Points

• Aurora Cannabis Inc. saw its stock price fall by 4.5% during mid-day trading, closing at C$7.40, down from the previous close of C$7.75.
• Senior Officer Andre Jerome purchased 8,000 shares at an average cost of C$5.83, indicating insider confidence in the stock.
• The company has a market cap of C$416.22 million and operates internationally through cannabis exporting agreements in over 20 countries.

Aurora Cannabis Inc. (TSE:ACB - ) fell 4.5% during mid-day trading on Monday . The stock traded as low as C$7.33 and last traded at C$7.40. 773,541 shares changed hands during mid-day trading, an increase of 34% from the average session volume of 575,176 shares. The stock had previously closed at C$7.75.

Aurora Cannabis Price Performance

The company has a fifty day simple moving average of C$6.48 and a 200-day simple moving average of C$6.72. The company has a market cap of C$416.22 million, a P/E ratio of -22.42 and a beta of 0.95. The company has a debt-to-equity ratio of 18.72, a current ratio of 3.42 and a quick ratio of 2.48.

Insider Activity

In related news, Senior Officer Andre Jerome bought 8,000 shares of the business's stock in a transaction dated Friday, June 20th. The shares were bought at an average cost of C$5.83 per share, with a total value of C$46,640.00.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.